Eilers Mark, Roy Upal, Mondal Debasis
Department of Pharmacology, Tulane University Health Sciences Center, 1430 Tulane Avenue, SL-83, New Orleans, LA 70112, USA.
Exp Biol Med (Maywood). 2008 Sep;233(9):1149-60. doi: 10.3181/0802-RM-59. Epub 2008 Jun 5.
The constituents of highly active anti-retroviral therapy (HAART) include HIV-1 protease inhibitors (HPIs) and nucleoside reverse transcriptase inhibitors (NRTIs). Endothelial cell (EC) barriers, especially the blood-brain-barrier (BBB) suppresses the entry of HAART drugs to subendothelial HIV-1 reservoirs. The ATP binding cassette (ABC) transporter family members, multidrug resistant-1 (MDR-1) and multidrug resistance-associated proteins (MRPs) can efflux both HPIs and NRTIs from intracellular compartments. Using brain derived ECs from non-human sources, previous studies suggested a dominant role for MDR-1 in HAART efflux from the BBB. However, due to species variations in ABC-transporter expression, drug-efflux functions using human brain ECs need to be investigated. Furthermore, roles of ABC-transporters in drug-efflux from systemic EC barriers need to be studied. We monitored the expression of ABC-transporters in primary human ECs obtained from brain (HBMVECs), aorta (HAECs), pulmonary-artery (HPAECs), dermal-microvessel (HDMVECs) and umbilical vein (HUVECs). Gene expression for MDR-1 and MRPs (MRP-1 to MRP-5) were analyzed by reverse transcriptase polymerase chain reaction (RT-PCR). Drug efflux functions were determined by calcein retention assays. Intracellular accumulation of both 3H-saquinavir (an HPI) and 3H-zidovudine (an NRTI) were also monitored in HAECs and HBMVECs. Both assays were carried out in presence of verapamil (20-60 microM) or MK-571 (12.5-50 microM) inhibitors of MDR-1 and MRPs, respectively in presence of verapamil or MK-571. The HBMVECs expressed higher levels of MRPs than MDR-1 and only MK-571 significantly (P<0.01) suppressed calcein efflux from these cells. However, both HAECs and HPAECs showed MDR-1 and MRP expression and calcein efflux was inhibited by both verapamil and MK-571. Both inhibitors suppressed 3H-saqubinavir efflux from HAECs, but only MK-571 suppressed saquinavir efflux from HBMVECs. In both ECs, 3H-zidovudine efflux was only suppressed by MK-571. Thus, primary human ECs, especially brain derived ECs, predominantly express MRPs and their specific inhibition may enhance HAART efficacy in subendothelial HIV-1 reservoirs.
高效抗逆转录病毒疗法(HAART)的成分包括HIV-1蛋白酶抑制剂(HPIs)和核苷类逆转录酶抑制剂(NRTIs)。内皮细胞(EC)屏障,尤其是血脑屏障(BBB)会抑制HAART药物进入内皮下的HIV-1储存库。ATP结合盒(ABC)转运蛋白家族成员,多药耐药蛋白1(MDR-1)和多药耐药相关蛋白(MRPs)可将HPIs和NRTIs从细胞内区室排出。先前使用非人类来源的脑源性ECs进行的研究表明,MDR-1在BBB对HAART的外排中起主导作用。然而,由于ABC转运蛋白表达存在物种差异,因此需要研究使用人脑ECs时的药物外排功能。此外,还需要研究ABC转运蛋白在全身EC屏障药物外排中的作用。我们监测了从脑(HBMVECs)、主动脉(HAECs)、肺动脉(HPAECs)、真皮微血管(HDMVECs)和脐静脉(HUVECs)获取的原代人ECs中ABC转运蛋白的表达。通过逆转录聚合酶链反应(RT-PCR)分析MDR-1和MRPs(MRP-1至MRP-5)的基因表达。通过钙黄绿素保留试验确定药物外排功能。还监测了HAECs和HBMVECs中3H-沙奎那韦(一种HPI)和3H-齐多夫定(一种NRTI)的细胞内积累。两种试验均分别在维拉帕米(20 - 60 microM)或MK-571(12.5 - 50 microM)(分别为MDR-1和MRPs的抑制剂)存在的情况下进行。HBMVECs表达的MRPs水平高于MDR-1,只有MK-57能显著(P<0.01)抑制这些细胞的钙黄绿素外排。然而,HAECs和HPAECs均显示有MDR-1和MRP表达,维拉帕米和MK-571均能抑制钙黄绿素外排。两种抑制剂均能抑制HAECs中3H-沙奎那韦的外排,但只有MK-571能抑制HBMVECs中沙奎那韦的外排。在两种ECs中,3H-齐多夫定的外排仅被MK-571抑制。因此,原代人ECs,尤其是脑源性ECs,主要表达MRPs,对其进行特异性抑制可能会增强HAART在内皮下HIV-1储存库中的疗效。